HC Wainwright Reiterates "Buy" Rating for Valneva (NASDAQ:VALN)

HC Wainwright reissued their buy rating on shares of Valneva (NASDAQ:VALN - Free Report) in a research report report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $17.00 price target on the stock.

Separately, Guggenheim lowered their price target on Valneva from $17.00 to $15.00 and set a "buy" rating for the company in a report on Monday, March 24th.

Valneva Stock Up 7.6 %

NASDAQ VALN traded up $0.48 during mid-day trading on Wednesday, reaching $6.77. 49,501 shares of the company's stock traded hands, compared to its average volume of 36,718. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a market cap of $550.14 million, a price-to-earnings ratio of -52.08 and a beta of 1.85. The company has a fifty day simple moving average of $6.98 and a 200-day simple moving average of $5.62.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $56.48 million for the quarter, compared to analyst estimates of $55.64 million. As a group, equities research analysts expect that Valneva will post 0.13 EPS for the current year.

Remove Ads

Institutional Trading of Valneva

Several hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC acquired a new position in Valneva during the 1st quarter valued at about $94,000. ABC Arbitrage SA acquired a new stake in Valneva in the 4th quarter valued at about $84,000. Finally, Wells Fargo & Company MN boosted its position in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after purchasing an additional 30,859 shares in the last quarter. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.